55455-92-0

Basic information

• Product Name: 1-(3-PHENYLPROPYL)PIPERAZINE
• Synonyms: RARECHEM AH CK 0164;TIMTEC-BB SBB003508;1-(3-PHENYLPROPYL)PIPERAZINE;Phenylpropylpiperazine;1-(3-Phenylpropyl)piperazine 98%;1-(3-Phenypropyl)piperazine
• CAS NO: 55455-92-0
• Molecular Formula: C₁₃H₂₀N₂
• Molecular Weight: 204.31
• Mol File: 55455-92-0.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 134 °C
• Flash Point: 137.1 °C
• Appearance: /
• Density: 0.98 g/cm³
• PKA: 9.24±0.10(Predicted)
• CAS DataBase Reference: 1-(3-PHENYLPROPYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-PHENYLPROPYL)PIPERAZINE(55455-92-0)
• EPA Substance Registry System: 1-(3-PHENYLPROPYL)PIPERAZINE(55455-92-0)

Safety Data

• Hazard Codes: Xi,T
• Statements: 36/37/38-25
• Safety Statements: 26-36/37/39-45
• Hazardous Substances Data: 55455-92-0(Hazardous Substances Data)

Usage

General Description

1-(3-Phenylpropyl)piperazine, also known as 3-PPP, is a chemical compound with a piperazine core and a phenylpropyl side chain. It belongs to the class of piperazine derivatives, which are commonly used in pharmaceutical drugs and research compounds. 1-(3-Phenylpropyl)piperazine has been studied for its potential as a drug candidate for a variety of medical conditions, including psychiatric disorders and neurological diseases. It exhibits affinity for certain neurotransmitter receptors in the brain, which may contribute to its pharmacological effects. Additionally, it has been investigated for its role in the synthesis of other organic compounds and as a precursor in chemical reactions. Due to its potential therapeutic applications and its role in chemical synthesis, 1-(3-Phenylpropyl)piperazine is a compound of interest for researchers and pharmaceutical developers.

Upstream product

• 637-59-2 1-Bromo-3-phenylpropane 
• 7542-23-6 piperazine hydrochloride 
• 117132-90-8 1-(3-phenylpropionyl)piperazine 
• 59698-38-3 4-(3-phenyl-propyl)-piperazine-1-carboxylic acid ethyl ester 
• 110-85-0 piperazine 
• 104-52-9 phenylpropyl chloride 
• 18903-01-0 trans-1-cinnamylpiperazine 
• 645-45-4 hydrocinnamic acid chloride 
• 501-52-0 3-Phenylpropionic acid 
• 100-42-5 styrene 
• 201230-82-2 carbon monoxide 
• 124-38-9 carbon dioxide 

Downstream Products

• 132019-73-9 N-(5,11-Dihydro-10-thia-dibenzo[a,d]cyclohepten-5-yl)-4-[4-(3-phenyl-propyl)-piperazin-1-yl]-butyramide 
• 198895-71-5 1-[N-(tert-butoxycarbonyl)aminoacetyl]-4-(3-phenylpropan-1-yl)piperazine 
• 219659-36-6 {4-Oxo-4-[4-(3-phenyl-propyl)-piperazin-1-yl]-butyl}-carbamic acid tert-butyl ester 
• 219659-35-5 {3-Oxo-3-[4-(3-phenyl-propyl)-piperazin-1-yl]-propyl}-carbamic acid tert-butyl ester 
• 219659-15-1 YZ 155-2 
• 219659-13-9 2-(2-Nitro-phenyl)-1-[4-(3-phenyl-propyl)-piperazin-1-yl]-ethanone 
• 219659-14-0 2-(3-Nitro-phenyl)-1-[4-(3-phenyl-propyl)-piperazin-1-yl]-ethanone 
• 219659-17-3 2-(3-Methoxy-phenyl)-1-[4-(3-phenyl-propyl)-piperazin-1-yl]-ethanone 

Relevant articles and documents

Design, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors

Monoamine transporters regulate the concentration of monoamine neurotransmitters, which are essential for vital physiological processes, and their dysfunction can cause several central nervous system diseases. Monoamine transporters currently appear to be the potential target in the management of these disorders. In this study, homologation and bioisosterism techniques have been used in the designing of new 1,4-disubstituted piperazines and piperidines. These derivatives were synthesized and evaluated as potential triple reuptake inhibitors for studying the structure-activity relationships. The most advanced compound, 1-(4-(5-benzhydryl-1H-tetrazol-1-yl)butyl)-4-(3-phenylpropyl)piperazine (2i), was able to inhibit monoamine neurotransmitter reuptake in an in vitro test (IC50?=?158.7?nM for 5-HT, 99?nM for NE and 97.5?nM for DA). These novel potent triple reuptake inhibitor-based 1,4-disubstituted piperazine and piperidine scaffolds deserve further systematic optimization and pharmacological evaluation.

Rhodium-Catalyzed Bis-Hydroaminomethylation of Linear Aliphatic Alkenes with Piperazine

An efficient protocol was developed to prepare a series of dialkylpiperazines via Rh-catalyzed bis-hydroaminomethylation of linear aliphatic alkenes with piperazine. The well-known Rh/Biphephos catalytic system was applied, yielding the desired dialkylpiperazines within six tandem catalytic steps, already at low catalyst loadings of 0.1 mol%. For the model alkene 1-octene, good yields and linearities of 80% and 77:23, respectively, were achieved under optimized conditions. Influences on the catalytic system regarding n/iso ratio, possible side reactions and the reaction path are discussed on the basis of yield vs. time plots and parameter optimization. With the developed general protocol, other linear, functionalized and branched substrates were effectively transformed to the corresponding linear N,N-disubstituted piperazines.

Synthesis and preliminary pharmacological evaluation of 4′-arylalkyl analogues of clozapine. II. Effect of the nature and length of the linker

We report the synthesis of a second generation of tricyclic analogues of clozapine, investigating the length and nature of the chain between an ionizable nitrogen atom at physiological pH and the introduced aryl moiety. The chemistry, structural characterization, and pharmacological evaluation of this series of 4′-arylalkyl analogues of clozapine are described. Preliminary findings on the effects on activity of the nature and length of the linker, degree of unsaturation, and type of aryl moiety on blockade of dopamine D4 and serotonin 5-HT2A receptors are discussed and animal behavioural data for key compounds presented.